OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D
February 28, 2022 04:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D Oxford, United Kingdom – 28 February 2022 – OMass Therapeutics (‘OMass’ or...
OMass Therapeutics to Present at Upcoming Conferences
February 21, 2022 04:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Therapeutics to Present at Upcoming Conferences Oxford, United Kingdom – 21 February 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying...
OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins
November 04, 2021 03:00 ET
|
OMass Therapeutics
PRESS RELEASE OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins Oxford, United Kingdom – 4 November 2021 – OMass...